PET/CT with 68Gallium-DOTA-peptides in NET: an overview.
In the present review article we presented the major technical innovations regarding the diagnosis of NET with PET/CT 68Ga-DOTA-peptides compounds over conventional radiologic and scintigraphic imaging, discussing both the different types of radiopharmaceuticals commercially available, trying to making a comparison on the possible advantages and drawbacks of these radiopharmaceuticals, and providing also some technical recommendations to the radiologists and nuclear physicians for using these new methodology in an appropriate manner in the clinical setting.
Ambrosini
Valentina
V
Department of Nuclear Medicine, Sant' Orsola-Malpighi University Hospital, Bologna, Italy.
Campana
Davide
D
Tomassetti
Paola
P
Grassetto
Gaia
G
Rubello
Domenico
D
Fanti
Stefano
S
D005710:Gallium Radioisotopes; D006801:Humans; D064847:Multimodal Imaging; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
C504894:68Ga-DOTANOC; D005710:Gallium Radioisotopes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals